Item 1(a). | Name of Issuer: |
Foamix Pharmaceuticals Ltd. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
2 Holzman Street, Weizmann Science Park, Rehovot, Israel
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Ordinary Shares, par value NIS 0.16 per share (“Ordinary Shares”)
M46135105
Item 3. | If this statement is filed pursuant to§§240.13d-1(b) or240.13d-2(b) or (c), checkwhether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 61,003,927 outstanding Ordinary Shares, as reported in the Issuer’s prospectus supplement filed on July 30, 2019.
The Master Fund directly holds 11,203,881 Ordinary Shares. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.